Linked Data API

Show Search Form

Search Results

1064443
registered interest false more like this
date less than 2019-02-20more like thismore than 2019-02-20
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Misuse more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of children under the age of 16 have had a (a) fatal and (b) non-fatal drug overdose in each of the last 10 years. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 223968 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-25more like thismore than 2019-02-25
answer text <p>The information in the format requested is not held centrally. The Office for National Statistics publishes an annual summary of all deaths related to drug poisoning (involving both legal and illegal drugs) and drug misuse (involving illegal drugs) in England and Wales. Data on deaths in those aged under 20 is grouped together. The reports are available at the following link:</p><p><a href="http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2017registrations" target="_blank">www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2017registrations</a></p><p>NHS Digital collects Hospital Episode Statistics regarding intentional self-poisoning that resulted in a hospital admission, however to provide this information for the last ten years would incur disproportionate costs.</p> more like this
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
grouped question UIN 223972 more like this
question first answered
less than 2019-02-25T17:33:35.657Zmore like thismore than 2019-02-25T17:33:35.657Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
1064447
registered interest false more like this
date less than 2019-02-20more like thismore than 2019-02-20
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Drugs: Misuse more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of children under the age of 18 that have had a (a) fatal and (b) non-fatal drug overdose in each of the last 10 years. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 223972 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-25more like thismore than 2019-02-25
answer text <p>The information in the format requested is not held centrally. The Office for National Statistics publishes an annual summary of all deaths related to drug poisoning (involving both legal and illegal drugs) and drug misuse (involving illegal drugs) in England and Wales. Data on deaths in those aged under 20 is grouped together. The reports are available at the following link:</p><p><a href="http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2017registrations" target="_blank">www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2017registrations</a></p><p>NHS Digital collects Hospital Episode Statistics regarding intentional self-poisoning that resulted in a hospital admission, however to provide this information for the last ten years would incur disproportionate costs.</p> more like this
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
grouped question UIN 223968 more like this
question first answered
less than 2019-02-25T17:33:35.7Zmore like thismore than 2019-02-25T17:33:35.7Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
1058873
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Breast Cancer: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of risk-stratified screening for breast cancer. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 219575 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>The United Kingdom National Screening Committee (UK NSC) has recently closed its three month public consultation on risk stratification to offer additional breast screening with ultrasound after a negative mammography in women with dense breasts.</p><p>The UK NSC will convene at the end of the month to review comments from this consultation and will advise accordingly. Minutes of the meeting are usually published six weeks after its meeting and will be made available on the UK NSC website at the following link:</p><p><a href="https://www.gov.uk/government/groups/uk-national-screening-committee-uk-nsc" target="_blank">https://www.gov.uk/government/groups/uk-national-screening-committee-uk-nsc</a></p> more like this
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T17:38:39.303Zmore like thismore than 2019-02-14T17:38:39.303Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
1058874
registered interest false more like this
date less than 2019-02-11more like thismore than 2019-02-11
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Radiology: Recruitment more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether the forthcoming NHS workforce implementation plan will include a plan to increase the numbers of NHS diagnostic radiographers. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 219576 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-02-14more like thismore than 2019-02-14
answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care has commissioned Baroness Dido Harding Chair of NHS Improvement, working closely with Sir David Behan, Chair of Health Education England, to lead a number of programmes to engage with key National Health Service interests to develop a detailed workforce implementation plan.</p><p> </p><p>This programme of work will consider detailed proposals to grow the workforce, including consideration of the additional staff and skills required to deliver round the clock high quality care. Baroness Harding and Sir David Behan will present initial recommendations to the Department in spring 2019. A final workforce implementation plan will follow later in the year, taking into account the outcomes of the Spending Review.</p><p> </p><p>Universities consistently continue to recruit students onto undergraduate diagnostic radiography university courses in England, with acceptances onto courses increasing every year since 2014. The latest NHS Digital data shows that as at October 2018 there are 3,084 more full time equivalent diagnostic radiographers in the NHS than there were in May 2010.</p><p> </p><p>Diagnostic radiographer education and training and recruitment in Wales, Northern Ireland and Scotland is a matter for the devolved governments in each nation.</p>
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
question first answered
less than 2019-02-14T17:46:54.503Zmore like thismore than 2019-02-14T17:46:54.503Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
1046081
registered interest false more like this
date less than 2019-01-22more like thismore than 2019-01-22
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps NHS England will take to encourage the uptake of innovative and cost-effective medicines as set out in the 2019 voluntary scheme for branded medicines pricing and access. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 211348 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-01-28more like thismore than 2019-01-28
answer text <p>The 2019 voluntary scheme for branded medicines pricing and access contains ambitions to improve patients’ outcomes and the health gain from medicines spend by simplifying, streamlining and improving access, pricing and uptake arrangements for cost-effective medicines; and delivering faster adoption of the most clinically and cost-effective medicines.</p><p>This will be supported by changes to the National Institute for Health and Care Excellence’s value assessment of new products, availability of increased commercial flexibility, and support for the National Health Service to increase uptake where appropriate. Use of products, particularly those which provide greatest health gain for patients, will be monitored and reviewed through this scheme. NHS England is developing a cohesive commercial framework to support this.</p> more like this
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
question first answered
less than 2019-01-28T17:19:33.147Zmore like thismore than 2019-01-28T17:19:33.147Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
1043706
registered interest false more like this
date less than 2019-01-18more like thismore than 2019-01-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Ocrelizumab more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what the status is of negotiations between Roche and NHS England on access to ocrelizumab for people with primary progressive MS on the NHS; and if he will take steps to help the two parties reach an agreement to deliver access to that drug. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 210045 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-01-23more like thismore than 2019-01-23
answer text <p>In November 2018, my Rt. hon. Friend the Secretary of State for Health and Social Care, met with Roche to discuss life sciences, and briefly discussed the negotiations between Roche and NHS England on ocrelizumab. Similarly, the former Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) met with Roche in December 2018. Both Ministers encouraged the on-going negotiations and agreed that these negotiations needed to continue in order to ensure the best conclusion for both parties, and patients that suffer from primary progressive multiple sclerosis. Those discussions are rightly for NHS England and Roche and it would not be appropriate for Ministers to intervene.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of ocrelizumab for the treatment of primary progressive multiple sclerosis. NHS England is in discussions with Roche, the manufacturer of ocrelizumab, to seek to agree a commercial agreement that might enable NICE to recommend use of the drug.</p>
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
grouped question UIN 210046 more like this
question first answered
less than 2019-01-23T16:22:30.1Zmore like thismore than 2019-01-23T16:22:30.1Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
1043707
registered interest false more like this
date less than 2019-01-18more like thismore than 2019-01-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Ocrelizumab more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) Roche and (b) NHS England on introducing a managed access scheme for ocrelizumab to made available for people living with primary progressive MS. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 210046 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-01-23more like thismore than 2019-01-23
answer text <p>In November 2018, my Rt. hon. Friend the Secretary of State for Health and Social Care, met with Roche to discuss life sciences, and briefly discussed the negotiations between Roche and NHS England on ocrelizumab. Similarly, the former Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) met with Roche in December 2018. Both Ministers encouraged the on-going negotiations and agreed that these negotiations needed to continue in order to ensure the best conclusion for both parties, and patients that suffer from primary progressive multiple sclerosis. Those discussions are rightly for NHS England and Roche and it would not be appropriate for Ministers to intervene.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of ocrelizumab for the treatment of primary progressive multiple sclerosis. NHS England is in discussions with Roche, the manufacturer of ocrelizumab, to seek to agree a commercial agreement that might enable NICE to recommend use of the drug.</p>
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
grouped question UIN 210045 more like this
question first answered
less than 2019-01-23T16:22:30.147Zmore like thismore than 2019-01-23T16:22:30.147Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
1011557
registered interest false more like this
date less than 2018-11-21more like thismore than 2018-11-21
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Complex Regional Pain Syndrome more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to raise awareness among health professionals of the new Royal College of Physicians Guidelines on complex regional pain syndrome. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 194180 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-26more like thismore than 2018-11-26
answer text <p>It is not the role of the Department to promote clinical guidance to health professionals. Health professionals, once qualified, are expected to stay informed about the latest evidence in clinical practice.</p><p> </p><p>The updated guidance on complex regional pain syndrome, published by the Royal College of Physicians was developed in partnership with 28 other organisations. A number of the organisations involved have sought to promote the guidance via online media and their respective websites. A copy of the guidance can be found at the following link:</p><p> </p><p><a href="http://www.rcplondon.ac.uk/guidelines-policy/complex-regional-pain-syndrome-adults" target="_blank">www.rcplondon.ac.uk/guidelines-policy/complex-regional-pain-syndrome-adults</a></p> more like this
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
question first answered
less than 2018-11-26T17:44:26.837Zmore like thismore than 2018-11-26T17:44:26.837Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
983378
registered interest false more like this
date less than 2018-10-08more like thismore than 2018-10-08
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Pharmaceutical Price Regulation Scheme more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the answer of 6 September 2018 to Question 169830 on Pharmaceutical Price Regulation Scheme, what progress he has made on an outline deal for the next Pharmaceutical Price Regulation Scheme. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 176660 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-10-11more like thismore than 2018-10-11
answer text <p>The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative medicines and technologies at a price the National Health Service can afford. Discussions on a branded medicines voluntary agreement for 2019 onwards are ongoing and are constructive.</p> more like this
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
question first answered
less than 2018-10-11T16:43:50.993Zmore like thismore than 2018-10-11T16:43:50.993Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this
964214
registered interest false more like this
date less than 2018-09-03more like thismore than 2018-09-03
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Pharmaceutical Price Regulation Scheme more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the next Pharmaceutical Price Regulation Scheme provides improved patient access to new and clinically effective medicines. more like this
tabling member constituency High Peak more like this
tabling member printed
Ruth George remove filter
uin 169829 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-09-06more like thismore than 2018-09-06
answer text <p>The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative medicines and technologies at a price the National Health Service can afford. Discussions on the 2019 Pharmaceutical Price Regulation Scheme have been constructive and we are continuing to make progress.</p><p> </p><p>During the pre-negotiation engagement phase the Department sought views from a wide range of organisations, including bodies representing patients, which informed our objectives for this agreement. We will seek to meet again with patient charities to discuss the development of a full agreement once an outline deal is reached. Due to commercial sensitivities the Department cannot share further details until the point where a heads of agreement is reached.</p> more like this
answering member constituency Winchester remove filter
answering member printed Steve Brine more like this
grouped question UIN 169830 more like this
question first answered
less than 2018-09-06T10:29:59.333Zmore like thismore than 2018-09-06T10:29:59.333Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4662
label Biography information for Ruth George more like this